Eiger BioPharmaceuticals Announces Results of Multiple Presentations at the European Association for the Study of the Liver (EASL) 2022 International Liver Congress™


PALO ALTO, Calif., June 27, 2022 /PRNewswire/ — Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on developing innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced data presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 which took place June 22-26 in London, United Kingdom.

Eiger BioPharmaceuticals (PRNewsFoto/Eiger BioPharmaceuticals, Inc.)

“We are delighted that EASL has recognized our HDV platform with multiple presentations this year highlighting both the lonafarnib and peginterferon lambda programs,” said David Cory, President and CEO, Eiger. “Our Phase 3 D-LIVR The study will produce the largest cohort of patient data from a well-controlled global HDV study. We look forward to continued collaboration with researchers and key opinion leaders to leverage this in-depth data set, providing additional insights, with the goal of improving outcomes for the global HDV patient population. At the same time, we are preparing the first results of the history D-LIVR study by the end of the year.”

Summary #3442: Predictive clinical characteristics of cirrhosis in a large cohort of patients with chronic hepatitis delta infection – Insights from the D-LIVR Test; Etzion, O., Asselah, T., Lampertico, P. et al.
Conclusion : In the current phase 3 D-LIVR study, the largest cohort to date of patients with chronic VHD, alarming rates of cirrhosis were observed in patients with compensated liver disease at a relatively young middle age. More than 40% of cirrhotic patients were ≤ 45 years old. A high index of suspicion for cirrhosis should be maintained in this population, particularly in elderly patients and in those with subtle changes in markers of synthetic liver function and portal hypertension.

Abstract #2072: Mathematical modeling of HDV RNA kinetics suggests high efficacy of peginterferon lambda in blocking viral production and infection: insights from the LIMT-1 Study; Cardozo-Ojeda, EF, Etzion, O. et al.
Conclusion : Previously reported end-of-study data from Phase 2 LIMIT-1 The peginterferon lambda (Lambda) monotherapy trial showed that Lambda therapy had better antiviral activity and better tolerability compared to historical data for peginterferon alfa and identified four main kinetic patterns of HDV RNA under Lambda therapy. This study provides, for the first time, a dynamic description of the HDV response under Lambda monotherapy. Lambda blocks viral production with great efficiency. The kinetics of HDV depends on the efficiency of Lambda, the basal fraction of uninfected hepatocytes and their proliferation rates.

Summary #1904: Combination of lonafarnib with peginterferon Lambda Decrease in the kinetic pattern of triphasic VHD observed under Lambda monotherapy: ELEVATOR-1 VHD study; Duehren, S., Dahari, H., Heller, T. et al.
Conclusion : Phase 2 end-of-study data ELEVATOR-1 A study of peginterferon lambda combined with lonafarnib has previously been reported (AASLD 2020). The objective of the present study was to characterize the kinetics of HDV RNA, HBV DNA, HBsAg and ALT during and after combination therapy. Combination therapy was associated with better treatment success (≥2 log decrease in HDV RNA) compared to Lambda monotherapy. No null responder with Lambda + Lonafarnib. The reduction in the triphasic kinetic pattern suggests that the addition of lonafarnib may decrease HDV RNA production/release. The kinetic patterns observed in Lambda + Lonafarnib and Lambda monotherapy are associated with treatment response.

About the Eiger

Eiger is a commercial-stage biopharmaceutical company focused on developing innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class Phase 3 therapies that target critical host processes involved in viral replication. Eiger is also developing peginterferon lambda as a therapeutic for COVID-19 and has reported positive results from TOGETHER, an investigator-initiated phase 3 study.

Eiger’s five rare disease programs have received FDA Breakthrough Therapy designation: lonafarnib and peginterferon lambda for HDV, Zokinvy for progeria, and avexitide for congenital hyperinsulinism and post-bariatric hypoglycemia.

For more information about Eiger and its clinical programs, please visit www.eigerbio.com.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding our future financial condition, timing and clinical outcome results, regulatory objectives, business strategy, and plans and objectives for future operations, are forward-looking statements. Forward-looking statements are our current statements regarding our intentions, beliefs, projections, outlook, analyzes or current expectations regarding, among other things, our anticipated milestones in 2022; the timing of our ongoing and planned clinical development; the adequacy of our cash, cash equivalents and investments to fund our operations; expectations regarding the timing and availability of key data from our Phase 3 D-LIVR study in HDV; our ability to fund the continued advancement of our development pipeline products; and the potential for success of each of our product candidates. Various important factors could cause actual results or events to differ materially from Eiger’s forward-looking statements, including additional applicable risks and uncertainties described in the “Risk Factors” sections of the Quarterly Report on Form 10-Q for the quarter. ended March 31, 2022 and Eiger’s subsequent SEC filings. The forward-looking statements contained in this press release are based on information currently available to Eiger and speak only as of the date on which they are made. Eiger does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events, changed circumstances or otherwise.

Sylvia Wheeler
Wheelhouse Life Science Advisors
[email protected]

Sarah Mathieson
SVP, Corporate Affairs
[email protected]



View original content to download multimedia: https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-announces-results-from-multiple-presentations-at-the-european-association-for-the-study -of-the-liver-easl-international-liver-congress-2022-301576119.html

SOURCEEiger BioPharmaceuticals, Inc.


Comments are closed.